A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT05929079
StatusCompleted
PhasePhase 3
SponsorEli Lilly and Company
Enrollment1,152 participants
DesignInterventional, Randomized, Parallel, Masking: Double
ConditionsType 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea
InterventionsRetatrutide; Placebo
StartJul 11, 2023
Primary completionJun 16, 2026
Study completionJun 16, 2026
Results postedNot yet
Registry last updatedJul 30, 2026

Compounds on this site that cite this trial

What the registry says the trial is about

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Percent Change from Baseline in Body WeightBaseline, Week 80
Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 SubsetBaseline, Week 80

14 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.

Share thisFacebookXEmail